Anika Therapeutics Inc.

As of June 30, 2026, Anika Therapeutics, Inc. carries a market capitalization of 168.98M, placing it among publicly traded companies globally. Its enterprise value stands at 157.46M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Anika Therapeutics, Inc.'s next confirmed earnings release is scheduled for October 29, 2026.

As of June 30, 2026, Anika Therapeutics, Inc. has 13.31M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 1.67, and the price-to-book ratio stands at 1.41.

As of June 30, 2026, Anika Therapeutics, Inc. trades at an EV/EBITDA multiple of 351.35 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.49 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 157.46M versus a market cap of 168.98M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Anika Therapeutics, Inc. maintains a current ratio of 4.48, meaning it holds 4.5x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Anika Therapeutics, Inc. posted a negative return on equity (ROE) of -2.66, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -2.04, reflecting losses generated across the asset base. The company generates approximately 425,411.67 in revenue per employee across its workforce of 248.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.01 indicates how many times Anika Therapeutics, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Anika Therapeutics, Inc. recorded 182,062.40 in income tax expense. The company reported a pretax loss of -2.55M and -3.31M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Anika Therapeutics, Inc.'s stock has gained approximately 125.45% over the past 52 weeks. The 50-day moving average sits at 18.08, while the 200-day moving average is 13.68.

Over the twelve months ended June 30, 2026, Anika Therapeutics, Inc. generated 105.61M in revenue and converted that into -3.31M in net income, yielding earnings per share of -0.19. EBITDA reached 448,153.60, while operating income came in at -4.48M.

As of June 30, 2026, Anika Therapeutics, Inc. holds 33.62M in cash and equivalents against 22.10M in total debt, resulting in a net debt position of -33.62M. Total book value stands at 120.16M, with working capital of 67.44M providing operational flexibility.

Anika Therapeutics, Inc. produced 5.23M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -4.74M in capital expenditures, free cash flow totaled 491,918.60 - equivalent to 0.04 per share.

Over the twelve months ended June 30, 2026, Anika Therapeutics, Inc. posted a gross margin of 62.16, reflecting its pricing power and cost economics. The operating margin of -4.24 and net profit margin of -3.14 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 0.28, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 8.46, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Anika Therapeutics, Inc. shareholders.

As of June 30, 2026, Anika Therapeutics, Inc. has an Altman Z-Score of 4.11, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.